SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: CrazyPete who wrote (530)3/7/2005 1:55:00 PM
From: Icebrg  Respond to of 946
 
The "official" comment to the failure to achieve superiority, seems to be that results in the treatment arm were negatively influenced due to patients being in a poorer condition (i.e. more negative prognostic factors applied to this group). That sounds somewhat farfetched to me.

However, even this does not explain why the control group did so much better than what historical "norms" seemed to indicate.

Erik



To: CrazyPete who wrote (530)3/7/2005 2:04:26 PM
From: Sam Citron  Respond to of 946
 
But were they dropping out less from the Xyotax arm due to reduced side-effects or because they simply wanted to give the new drug a chance to see if it was going to be any more effective? [maybe we will never know]

Sam


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News